Abstract
Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent vasoactive peptide, released from high molecular weight kininogen when it is cleaved by plasma kallikrein a serine protease controlled by C1-INH. Autoantibodies inactivating C1-INH are detected in the majority of patients and account for the deficiency. Irrespectively to the presence of anti-C1-INH autoantibodies lymphoproliferative diseases, ranging from benign monoclonal gammopathies to malignant lymphoma, are frequently associated with AAE. Demonstration that monoclonal components correspond to anti-C1-INH autoantibodies and correlation between course of lymphoma and course of AAE provide strong support to consider the two diseases expression of the same pathologic process.
Keywords: Angioedema, C1 inhibitor, lymphoma, autoimmunity, vascular permeability, bradykinin, contact system
Current Molecular Medicine
Title: The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Volume: 10 Issue: 4
Author(s): M. Cicardi and A. Zanichelli
Affiliation:
Keywords: Angioedema, C1 inhibitor, lymphoma, autoimmunity, vascular permeability, bradykinin, contact system
Abstract: Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent vasoactive peptide, released from high molecular weight kininogen when it is cleaved by plasma kallikrein a serine protease controlled by C1-INH. Autoantibodies inactivating C1-INH are detected in the majority of patients and account for the deficiency. Irrespectively to the presence of anti-C1-INH autoantibodies lymphoproliferative diseases, ranging from benign monoclonal gammopathies to malignant lymphoma, are frequently associated with AAE. Demonstration that monoclonal components correspond to anti-C1-INH autoantibodies and correlation between course of lymphoma and course of AAE provide strong support to consider the two diseases expression of the same pathologic process.
Export Options
About this article
Cite this article as:
Cicardi M. and Zanichelli A., The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791317066
DOI https://dx.doi.org/10.2174/156652410791317066 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypersensitivity Reactions to Complementary and Alternative Medicine Products
Current Pharmaceutical Design Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
Current Pharmaceutical Design Malaria in Children - Prevention and Management
Infectious Disorders - Drug Targets Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Drug Metabolism Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
Current Clinical Pharmacology Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Current Diabetes Reviews Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Cold-induced Anaphylaxis: The Case of a 9-year-old Child and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Healthcare Management During A Pandemic: The Other Side of the Coin for the Treatment of COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets